In conclusion, we have described a new highly sensitive and specific method for molecular monitoring of atypical BCR–ABL1 fusion transcripts in CML patients that helps in the definition of MRD levels to better delineate a therapeutic strategy and the optimal time for discontinuation. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.